Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02116946 · ClinicalTrials.gov registry record · Phase 2
Plasma Injections Plus Exercise for Patellar Tendinopathy
A Phase 2 study, sponsored by University of British Columbia.
- Terminated
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02116946: Clinical Trial Phase 2 study, sponsored by University of British Columbia.
NCT02116946 is a Phase 2 study that was terminated before completion, run by University of British Columbia. The registered enrollment target is 64 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02116946, a Phase 2 study, was terminated before completion, sponsored by University of British Columbia.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a randomized controlled clinical trial to investigate the effectiveness, safety and tolerability of platelet-rich plasma (PRP) injections for treatment of patellar tendinopathy in adults 18-50 years of age. Subjects will be randomly assigned to three parallel treatment groups: 1. Leukocyte-rich PRP injection + exercise 2. Leukocyte-poor PRP injection + exercise 3. Saline injection + exercise (control) Primary endpoints are (1) the number (rate) and severity of adverse events as reported by both patients and study physicians during the first 12 weeks after initiation of treatment, (2) patient-rated tolerability of treatment; (3) the change in function (VISA score) and treatment success (global improvement scale) over six months of a post-injection exercise protocol.
Primary Outcome
Number and frequency of adverse events will be assessed/reported weekly for the first 12 weeks and at the 6 month visit.
Interventions
- BIOLOGICAL Platelet Rich Plasma (PRP)
- OTHER Saline + exercise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-03 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
Why NCT02116946 stopped before completion
NCT02116946 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 2 interventions - of which Platelet Rich Plasma (PRP) is the first listed.
NCT02116946 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02116946 about?
NCT02116946 is a clinical study titled "Plasma Injections Plus Exercise for Patellar Tendinopathy". This is a randomized controlled clinical trial to investigate the effectiveness, safety and tolerability of platelet-rich plasma (PRP) injections for treatment of patellar tendinopathy in adults 18-50 years of age. Subjects will be randomly assigned to three parallel treatment groups: 1. Leukocyte-...
What is the current status of trial NCT02116946?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2014-03. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02116946?
The interventions under investigation include: Platelet Rich Plasma (PRP) (BIOLOGICAL), Saline + exercise (OTHER).
Who is sponsoring clinical trial NCT02116946?
This trial is sponsored by University of British Columbia, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02116946's enrollment target sits among peer trials
64 996th of 2000 higher than 992 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia